Research programme: apolipoprotein E mimetic peptides - LipimetiX Development
Alternative Names: AEM 28 02; AEM-28-08; AEM-28-14Latest Information Update: 25 Apr 2023
Price :
$50 *
At a glance
- Originator University of Alabama at Birmingham
- Developer LipimetiX Development
- Class Peptides
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary artery disease; Hypercholesterolaemia; Peripheral arterial disorders
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Hypercholesterolaemia in USA (IV)
- 25 Apr 2023 Discontinued for Coronary artery disease in USA (unspecified route)
- 25 Apr 2023 Discontinued for Peripheral arterial disorders in USA (unspecified route)